ACS to establish breast cancer and cervical cancer roundtables

FDA approves Ponlimsi to increase bone mass, including for breast and prostate cancer patients

FDA has approved Ponlimsi (denosumab-adet) as a biosimilar to Prolia.

April 03, 2026

Colorectal cancer is now the leading cause of cancer death in patients under 50
Why aren’t 45-year-olds getting their recommended CRC screenings?

Three decades ago, colorectal cancer was the fifth leading cause of cancer death in patients under 50 years old. For a physician treating the average 45-year-old, colorectal cancer was not a diagnosis that immediately came to mind.

Combination treatment benefits patients with leptomeningeal metastases from breast cancer, MD Anderson study finds

Patients with leptomeningeal metastasis have historically had few treatment options. Now, researchers from The University of Texas MD Anderson Cancer Center have found a combination of targeted therapies, tucatinib and trastuzumab, plus the chemotherapy drug, capecitabine, may improve symptoms and extend survival in some breast cancer patients with LM.

March 27, 2026

Vol.52 No.12

Clinical Roundup

Merck to present long-term data of Gardasil 9 and Gardasil at the EUROGIN international multidisciplinary HPV Congress

Clinical, real-world data reaffirming the long-term effectiveness of Gardasil 9 (Human Papillomavirus 9-valent Vaccine, Recombinant) and Gardasil (Human Papillomavirus 4-valent Vaccine, Recombinant) against certain HPV-related cancers and diseases will be presented at the EUROGIN International Multidisciplinary HPV Congress 2026 in Vienna, Austria, March 18-21.

March 20, 2026

Vol.52 No.11

Clinical Roundup

Atirmociclib combination produces positive topline results in phase II trial in second-line MBC indication

Positive topline results have come out of the randomized phase II FOURLIGHT-1 study evaluating atirmociclib in combination with fulvestrant, versus fulvestrant or everolimus plus exemestane, in people with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer who had received prior cyclin-dependent kinase 4/6 inhibitor-based treatment.

March 20, 2026

Vol.52 No.11

Guest Editorial

As more people are surviving cancer, we must continue funding bold science

The cancer research community has a reason to celebrate. For the first time, 70% of people are living at least five years beyond their cancer diagnosis. And, as importantly, cancer death rates have been dropping relentlessly—by more than a third since 1991.

March 13, 2026

Vol.52 No.10

By Karen E. Knudsen

ACS to establish breast cancer and cervical cancer roundtables

YOU MAY BE INTERESTED IN

FDA approves Ponlimsi to increase bone mass, including for breast and prostate cancer patients

Colorectal cancer is now the leading cause of cancer death in patients under 50
Why aren’t 45-year-olds getting their recommended CRC screenings?

Combination treatment benefits patients with leptomeningeal metastases from breast cancer, MD Anderson study finds

Merck to present long-term data of Gardasil 9 and Gardasil at the EUROGIN international multidisciplinary HPV Congress

Atirmociclib combination produces positive topline results in phase II trial in second-line MBC indication

As more people are surviving cancer, we must continue funding bold science

Renew today!

Subscriber content

Never miss an issue!

Login

ACS to establish breast cancer and cervical cancer roundtables

YOU MAY BE INTERESTED IN

FDA approves Ponlimsi to increase bone mass, including for breast and prostate cancer patients

Colorectal cancer is now the leading cause of cancer death in patients under 50Why aren’t 45-year-olds getting their recommended CRC screenings?

Combination treatment benefits patients with leptomeningeal metastases from breast cancer, MD Anderson study finds

Merck to present long-term data of Gardasil 9 and Gardasil at the EUROGIN international multidisciplinary HPV Congress

Atirmociclib combination produces positive topline results in phase II trial in second-line MBC indication

As more people are surviving cancer, we must continue funding bold science

Never miss an issue!

Login

Colorectal cancer is now the leading cause of cancer death in patients under 50
Why aren’t 45-year-olds getting their recommended CRC screenings?